The network started in September 2008 and will run over 4 years. The main scientific goals of this network are to enhance our knowledge of the mechanisms determining response outcome of existing immunomodulatory therapies for MS, and to identify novel therapeutic opportunities.
UEPHA-MS is composed of ten internationally recognised research teams from 5 countries with an assortment of expertise in complementary disciplines. The UEPHA-MS network will provide a coherent and internationally competitive platform for training of young scientists based on multi-disciplinary state-of-the-art lab-based and network-wide activities, and will be crucial in priming young scientists for Europe's collective effort toward improved provision of health care based on personalized medicine.
Multiple sclerosis (MS) is a disabling condition affecting the central nervous system, for which no definitive cure is available. Current therapies tend to be only partially effective.
The UEPHA*MS consortium, by combining expertise in genomics, biomarker research, proteomics, gene expression analysis / transcriptomics, bioinformatics and systems biology, will investigate the mechanisms that determine why some MS patients respond better to therapies, or with less adverse effects, than others.
It will also try to identify novel therapeutic opportunities for treatment of MS.
Visit to Progenika Biopharma SA and Biokabi bioincubator (Derio, Spain),
and meeting with local MS Charity (February - March 2011)
UEPHA*MS Summer School 3 "The Clinical Validation Process" + Transferable Skills Training "Entrepreneurship & IPR" (Berlin, Germany)
Open to external attendees (September 2011)
 |
United Europeans for the development of PHArmacogenomics in Multiple Sclerosis (UEPHA*MS) is a Marie Curie Initial Training Network funded by the EC 7th Framework Programme
